Abstract
Background The Abbott RealTi me HCV assay for quantitative detection of HCV RNA has recently been introduced. Objectives In this study, the performance of the Abbott RealTi me HCV assay was evaluated and compared to the COBAS AmpliPrep/COBAS TaqMan HCV test. Study design Accuracy, linearity, interassay and intra-assay variations were determined, and a total of 243 routine clinical samples were investigated. Results When accuracy of the new assay was tested, the majority of results were found to be within ±0.5 log 10 unit of the results obtained by reference laboratories. Determination of linearity resulted in a quasilinear curve up to 1.0 × 10 6 IU/ml. The interassay variation ranged from 15% to 32%, and the intra-assay variation ranged from 5% to 8%. When clinical samples were tested by the Abbott RealTi me HCV assay and the results were compared with those obtained by the COBAS AmpliPrep/COBAS TaqMan HCV test, the results for 93% of all samples with positive results by both tests were found to be within ±1.0 log 10 unit. The viral loads for all patients measured by the Abbott and Roche assays showed a high correlation ( R 2 = 0.93); quantitative results obtained by the Abbott assay were found to be lower than those obtained by the Roche assay. Conclusions The Abbott RealTi me HCV assay proved to be suitable for use in the routine diagnostic laboratory. The time to results was similar for both of the assays.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
